Convalescent Plasma for Patients With COVID-19: A Pilot Study
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Change in Viral Load
研究概览
简要总结
Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases. In the latest viral epidemics, such as the Ebola outbreak in West Africa in 2014, the World Health Organization issued a document outlining a protocol for the use of whole blood or plasma collected from patients who have recovered from the Ebola virus disease by transfusion to empirically treat local infectious outbreaks.
详细描述
The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). Our group has reviewed the scientific evidence regarding the application of convalescent plasma for emergency viral outbreaks and has recommended the following protocol
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fulfilling all the following criteria
- •Aged between 18 and 60 years, male or female.
- •Hospitalized participants with diagnosis for COVID 19 by Real Time - Polymerase Chain Reaction.
- •Without treatment.
- •Moderate cases according to the official guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)".
- •Confusion, Urea, Respiratory rate, Blood pressure-65 (CURB-65) >=
- •Sequential Organ Failure Assessment score (SOFA) <
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Female subjects who are pregnant or breastfeeding.
- •Patients with prior allergic reactions to transfusions.
- •Critical ill patients in intensive care units.
- •Patients with surgical procedures in the last 30 days.
- •Patients with active treatment for cancer (Radiotherapy or Chemotherapy).
- •HIV diagnosed patients with viral failure (detectable viral load> 1000 copies / ml persistent, two consecutive viral load measurements within a 3 month interval, with medication adherence between measurements after at least 6 months of starting a new regimen antiretrovirals).
- •Patients who have suspicion or evidence of coinfections.
- •End-stage chronic kidney disease (Glomerular Filtration Rate <15 ml / min / 1.73 m2).
- •Child Pugh C stage liver cirrhosis.
- •High cardiac output diseases.
- •Autoimmune diseases or Immunoglobulin A nephropathy.
- •Patients have any condition that in the judgement of the Investigators would make the subject inappropriate for entry into this study.
研究组 & 干预措施
Intervention Group
Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol.
干预措施: Plasma (Drug)
结局指标
主要结局
Change in Viral Load
时间窗: Days 0, 4, 7, 14 and 28
Copies of COVID-19 per ml
Change in Immunoglobulin M COVID-19 antibodies Titers
时间窗: Days 0, 4, 7, 14 and 28
Immunoglobulin M COVID-19 antibodies
Change in Immunoglobulin G COVID-19 antibodies Titers
时间窗: Days 0, 4, 7, 14 and 28
Immunoglobulin G COVID-19 antibodies
次要结局
- Intensive Care Unit Admission(Days 7, 14 and 28)
- Length of Intensive Care Unit stay(Days 7, 14 and 28)
- Length of hospital stay (days)(Days 7, 14 and 28)
- Requirement of mechanical ventilation(Days 7, 14 and 28)
- Duration (days) of mechanical ventilation(Days 7, 14 and 28)
- Clinical status assessed according to the World Health Organization guideline(Days 7, 14 and 28)
- Mortality(Days 7, 14 and 28)
研究者
Juan Manuel Anaya Cabrera
MD, PhD, Principal Investigator
Universidad del Rosario